Skip to main content
Top
Published in: Endocrine 1/2022

01-04-2022 | Glucocorticoid | Original Article

High incidence of hypertension-mediated organ damage in a series of Chinese patients with 17α-hydroxylase deficiency

Authors: Zhiyuan Zhao, Lin Lu, Ou Wang, Xueyan Wu, Bang Sun, Wei Zhang, Xi Wang, Jiangfeng Mao, Shi Chen, Anli Tong, Min Nie

Published in: Endocrine | Issue 1/2022

Login to get access

Abstract

Objective

To analyze the prevalence of hypertension-mediated organ damage (HMOD) and its relationship with enzyme activity of mutant CYP17A1 and other risk factors in patients with 17α-hydroxylase/17,20-lyase deficiency (17-OHD).

Methods

A total of 68 patients with 17-OHD were recruited in the Peking Union Medical College Hospital from 2003 to 2021. The incidence of hypertension and HMOD was respectively analyzed. CYP17A1 sequencing was performed and the enzyme activity of mutant CYP17A1 was determined by analyzing the characteristics of mutation itself and the functional data reported previously. A logistic regression model was employed to analyze the factors related to HMOD and the specific damaged organs in 17-OHD patients.

Result(s)

Sixty-five patients (95.6%) exhibited hypertension, 32 of whom were diagnosed with HMOD. c.985_987delTACinsAA (p.Y329KfsX418) (53.8%) and c.1459_1467del (p. del D487_F489) (11.4%) were the top two mutations, and no correlation was found between enzyme activity of mutant CYP17A1 and HMOD. The risk of HMOD increased by 32% for each additional year of hypertension duration, 10.2-fold for each one-grade increase in hypertension level, 2.3-fold for each grade of exacerbation of hypokalemia.

Conclusion

Patients with 17-OHD experience a high incidence of HMOD. There was no correlation between the HMOD occurrence and enzyme activity of mutant CYP17A1. Longer duration of hypertension, more severe hypertension, and hypokalemia were independent risk factors for the occurrence of HMOD in patients with 17-OHD.
Appendix
Available only for authorised users
Literature
1.
go back to reference D. EL-Maouche, W. Arlt, D.P. Merke, Congenital adrenal hyperplasia. Lancet 390(10108), 2194–2210 (2017)CrossRef D. EL-Maouche, W. Arlt, D.P. Merke, Congenital adrenal hyperplasia. Lancet 390(10108), 2194–2210 (2017)CrossRef
2.
go back to reference C.E. Kater, E.G. Biglieri, Disorders of steroid 17 alpha-hydroxylase deficiency. Endocrinol. Metab. Clin. North Am. 23(2), 341–357 (1994)CrossRef C.E. Kater, E.G. Biglieri, Disorders of steroid 17 alpha-hydroxylase deficiency. Endocrinol. Metab. Clin. North Am. 23(2), 341–357 (1994)CrossRef
3.
go back to reference W.L. Miller, R.J. Auchus, D.H. Geller, The regulation of 17,20 lyase activity. Steroids 62(1), 133–142 (1997)CrossRef W.L. Miller, R.J. Auchus, D.H. Geller, The regulation of 17,20 lyase activity. Steroids 62(1), 133–142 (1997)CrossRef
4.
go back to reference B.C. Chung, J. Picado-Leonard, M. Haniu et al. Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc. Natl. Acad. Sci. U S A. 84(2), 407–411 (1987)CrossRef B.C. Chung, J. Picado-Leonard, M. Haniu et al. Cytochrome P450c17 (steroid 17 alpha-hydroxylase/17,20 lyase): cloning of human adrenal and testis cDNAs indicates the same gene is expressed in both tissues. Proc. Natl. Acad. Sci. U S A. 84(2), 407–411 (1987)CrossRef
5.
go back to reference R.J. Auchus, Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic. J. Steroid. Biochem. Mol. Biol. 165(Pt A), 71–78 (2017)CrossRef R.J. Auchus, Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic. J. Steroid. Biochem. Mol. Biol. 165(Pt A), 71–78 (2017)CrossRef
6.
go back to reference T. Yanase, E.R. Simpson, M.R. Waterman, 17 alpha-hydroxylase/17,20-lyase deficiency: from clinical investigation to molecular definition. Endocr. Rev. 12(1), 91–108 (1991)CrossRef T. Yanase, E.R. Simpson, M.R. Waterman, 17 alpha-hydroxylase/17,20-lyase deficiency: from clinical investigation to molecular definition. Endocr. Rev. 12(1), 91–108 (1991)CrossRef
7.
go back to reference R. Fontenele, M. Costa-Santos, C.E. Kater, 17alpha-hydroxylase deficiency is an underdiagnosed disease: high frequency of misdiagnoses in a large cohort of brazilian patients. Endocr. Pract. 24(2), 170–178 (2018)CrossRef R. Fontenele, M. Costa-Santos, C.E. Kater, 17alpha-hydroxylase deficiency is an underdiagnosed disease: high frequency of misdiagnoses in a large cohort of brazilian patients. Endocr. Pract. 24(2), 170–178 (2018)CrossRef
8.
go back to reference L. Hinz, D. Pacaud, G. Kline, Congenital adrenal hyperplasia causing hypertension: an illustrative review. J. Hum. Hypertens. 32(2), 150–157 (2018)CrossRef L. Hinz, D. Pacaud, G. Kline, Congenital adrenal hyperplasia causing hypertension: an illustrative review. J. Hum. Hypertens. 32(2), 150–157 (2018)CrossRef
9.
go back to reference B. Williams, G. Mancia, W. Spiering et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 39(33), 3021–3104 (2018)CrossRef B. Williams, G. Mancia, W. Spiering et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 39(33), 3021–3104 (2018)CrossRef
10.
go back to reference Unger T., Borghi C., Charchar F. et al. 2020 International society of hypertension global hypertension practice guidelines. J. Hypertens. 38, 982–1004 (2020). Unger T., Borghi C., Charchar F. et al. 2020 International society of hypertension global hypertension practice guidelines. J. Hypertens. 38, 982–1004 (2020).
11.
go back to reference S.V. Greve, M.K. Blicher, T. Sehestedt et al. Effective risk stratification in patients with moderate cardiovascular risk using albuminuria and atherosclerotic plaques in the carotid arteries. J. Hypertens. 33(8), 1563–1570 (2015)CrossRef S.V. Greve, M.K. Blicher, T. Sehestedt et al. Effective risk stratification in patients with moderate cardiovascular risk using albuminuria and atherosclerotic plaques in the carotid arteries. J. Hypertens. 33(8), 1563–1570 (2015)CrossRef
12.
go back to reference P. Perrone-Filardi, A. Coca, M. Galderisi et al. Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus article from the European Association of Cardiovascular Imaging, the European Society of Cardiology Council on Hypertension and the Euro. J. Hypertens. 35(9), 1727–1741 (2017)CrossRef P. Perrone-Filardi, A. Coca, M. Galderisi et al. Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus article from the European Association of Cardiovascular Imaging, the European Society of Cardiology Council on Hypertension and the Euro. J. Hypertens. 35(9), 1727–1741 (2017)CrossRef
13.
go back to reference B.H. Van Den Born, G.Y.H. Lip, J. Brguljan-Hitij et al. ESC council on hypertension position document on the management of hypertensive emergencies. Eur. Heart J. Cardiovasc. Pharmacother. 5(1), 37–46 (2019)CrossRef B.H. Van Den Born, G.Y.H. Lip, J. Brguljan-Hitij et al. ESC council on hypertension position document on the management of hypertensive emergencies. Eur. Heart J. Cardiovasc. Pharmacother. 5(1), 37–46 (2019)CrossRef
14.
go back to reference G. De Simone, R.B. Devereux, R. Izzo et al. Lack of reduction of left ventricular mass in treated hypertension: the strong heart study. J. Am. Heart Assoc. 2(3), e000144 (2013)CrossRef G. De Simone, R.B. Devereux, R. Izzo et al. Lack of reduction of left ventricular mass in treated hypertension: the strong heart study. J. Am. Heart Assoc. 2(3), e000144 (2013)CrossRef
15.
go back to reference M.T. Lonnebakken, R.Izzo, C.Mancusi, et al. Left ventricular hypertrophy regression during antihypertensive treatment in an outpatient clinic (the Campania Salute Network). J. Am. Heart Assoc 6(3), e004152 (2017).CrossRef M.T. Lonnebakken, R.Izzo, C.Mancusi, et al. Left ventricular hypertrophy regression during antihypertensive treatment in an outpatient clinic (the Campania Salute Network). J. Am. Heart Assoc 6(3), e004152 (2017).CrossRef
16.
go back to reference H. Triantafyllidi, D. Be Nas, A. Schoinas, et al. Hypertension-mediated organ damage regression associates with blood pressure variability improvement three years after successful treatment initiation in essential hypertension. J. Clin. Hypertens (Greenwich) 23(6), 1150–1158 (2021).CrossRef H. Triantafyllidi, D. Be Nas, A. Schoinas, et al. Hypertension-mediated organ damage regression associates with blood pressure variability improvement three years after successful treatment initiation in essential hypertension. J. Clin. Hypertens (Greenwich) 23(6), 1150–1158 (2021).CrossRef
17.
go back to reference M. Zhang, S. Sun, Y. Liu et al. New, recurrent, and prevalent mutations: Clinical and molecular characterization of 26 Chinese patients with 17alpha-hydroxylase/17,20-lyase deficiency. J. Steroid Biochem. Mol. Biol. 150, 11–16 (2015)CrossRef M. Zhang, S. Sun, Y. Liu et al. New, recurrent, and prevalent mutations: Clinical and molecular characterization of 26 Chinese patients with 17alpha-hydroxylase/17,20-lyase deficiency. J. Steroid Biochem. Mol. Biol. 150, 11–16 (2015)CrossRef
18.
go back to reference C.S. Marivania, C.E. Kater, R.J. Auchus, Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-Hydroxylase deficiency. J. Clin. Endocrinol. Metabol. 1, 49–60 (2004) C.S. Marivania, C.E. Kater, R.J. Auchus, Two prevalent CYP17 mutations and genotype-phenotype correlations in 24 Brazilian patients with 17-Hydroxylase deficiency. J. Clin. Endocrinol. Metabol. 1, 49–60 (2004)
19.
go back to reference X. Zhang, M. Zhang, Z. Zhao et al. Geographic variation in prevalence of adult obesity in China: results from the 2013–2014 national chronic disease and risk factor surveillance. Ann. Intern. Med. 172(4), 291–293 (2020)CrossRef X. Zhang, M. Zhang, Z. Zhao et al. Geographic variation in prevalence of adult obesity in China: results from the 2013–2014 national chronic disease and risk factor surveillance. Ann. Intern. Med. 172(4), 291–293 (2020)CrossRef
20.
21.
go back to reference A.J. Viera, N. Wouk, Potassium disorders: hypokalemia and hyperkalemia. Am. Fam. Physician 92(6), 487–495 (2015)PubMed A.J. Viera, N. Wouk, Potassium disorders: hypokalemia and hyperkalemia. Am. Fam. Physician 92(6), 487–495 (2015)PubMed
22.
go back to reference J. Ashurst, S.R. Sergent, B.R. Sergent, Evidence-based management of potassium disorders in the emergency department. Emerg. Med. Pract. 18(11), 1–24 (2016)PubMed J. Ashurst, S.R. Sergent, B.R. Sergent, Evidence-based management of potassium disorders in the emergency department. Emerg. Med. Pract. 18(11), 1–24 (2016)PubMed
23.
go back to reference Chinese Hypertension Prevention and Treatment Guidelines Revision Committee H U C, Cardiology Branch of Chinese Medical Association. Chinese Guidelines for the Prevention and Treatment of Hypertension (2018 Revised Edition). Chin J. Cardiovasc Med. 24(1), 25 (2009). Chinese Hypertension Prevention and Treatment Guidelines Revision Committee H U C, Cardiology Branch of Chinese Medical Association. Chinese Guidelines for the Prevention and Treatment of Hypertension (2018 Revised Edition). Chin J. Cardiovasc Med. 24(1), 25 (2009).
24.
go back to reference C.A. Marsh, R.J. Auchus, Fertility in patients with genetic deficiencies of cytochrome P450c17 (CYP17A1): combined 17-hydroxylase/17,20-lyase deficiency and isolated 17,20-lyase deficiency. Fertil. Steril. 101(2), 317–322 (2014)CrossRef C.A. Marsh, R.J. Auchus, Fertility in patients with genetic deficiencies of cytochrome P450c17 (CYP17A1): combined 17-hydroxylase/17,20-lyase deficiency and isolated 17,20-lyase deficiency. Fertil. Steril. 101(2), 317–322 (2014)CrossRef
25.
go back to reference Y.P. Wang, J. Li, J.X. Li et al. Three novel CYP17A1 gene mutations (A82D, R125X, and C442R) found in combined 17α-hydroxylase/17,20-lyase deficiency. Metabolism 60(10), 1386–1391 (2011)CrossRef Y.P. Wang, J. Li, J.X. Li et al. Three novel CYP17A1 gene mutations (A82D, R125X, and C442R) found in combined 17α-hydroxylase/17,20-lyase deficiency. Metabolism 60(10), 1386–1391 (2011)CrossRef
26.
go back to reference N. Laflamme, J.F. Leblanc, J. Mailloux et al. Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-hydroxylase/17-20-lyase deficiency in two French Canadian patients. J. Clin. Endocrinol. Metab. 81(1), 264–268 (1996)CrossRef N. Laflamme, J.F. Leblanc, J. Mailloux et al. Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-hydroxylase/17-20-lyase deficiency in two French Canadian patients. J. Clin. Endocrinol. Metab. 81(1), 264–268 (1996)CrossRef
27.
go back to reference N. Nájera, N. Garibay, Y. Pastrana et al. Loss of cytochrome P450 17A1 protein expression in a 17alpha-hydroxylase/17,20-lyase-deficient 46,XY female caused by two novel mutations in the CYP17A1 gene. Endocr. Pathol. 20(4), 249–255 (2009)CrossRef N. Nájera, N. Garibay, Y. Pastrana et al. Loss of cytochrome P450 17A1 protein expression in a 17alpha-hydroxylase/17,20-lyase-deficient 46,XY female caused by two novel mutations in the CYP17A1 gene. Endocr. Pathol. 20(4), 249–255 (2009)CrossRef
28.
go back to reference E.L. Van Den Akker, J.W. Koper, A.L. Boehmer et al. Differential inhibition of 17alpha-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency. J. Clin. Endocrinol. Metab. 87(12), 5714–5721 (2002)CrossRef E.L. Van Den Akker, J.W. Koper, A.L. Boehmer et al. Differential inhibition of 17alpha-hydroxylase and 17,20-lyase activities by three novel missense CYP17 mutations identified in patients with P450c17 deficiency. J. Clin. Endocrinol. Metab. 87(12), 5714–5721 (2002)CrossRef
29.
go back to reference Y.M. Kim, M. Kang, J.H. Choi et al. A review of the literature on common CYP17A1 mutations in adults with 17-hydroxylase/17,20-lyase deficiency, a case series of such mutations among Koreans and functional characteristics of a novel mutation. Metabolism 63(1), 42–49 (2014)CrossRef Y.M. Kim, M. Kang, J.H. Choi et al. A review of the literature on common CYP17A1 mutations in adults with 17-hydroxylase/17,20-lyase deficiency, a case series of such mutations among Koreans and functional characteristics of a novel mutation. Metabolism 63(1), 42–49 (2014)CrossRef
30.
go back to reference K. Miura, K. Yasuda, T. Yanase et al. Mutation of cytochrome P-45017 alpha gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive hyperaldosteronism: with a review of Japanese patients with mutations of CYP17. J. Clin. Endocrinol. Metab. 81(10), 3797–3801 (1996)PubMed K. Miura, K. Yasuda, T. Yanase et al. Mutation of cytochrome P-45017 alpha gene (CYP17) in a Japanese patient previously reported as having glucocorticoid-responsive hyperaldosteronism: with a review of Japanese patients with mutations of CYP17. J. Clin. Endocrinol. Metab. 81(10), 3797–3801 (1996)PubMed
31.
go back to reference S. Ardhanari, R. Kannuswamy, K. Chaudhary et al. Mineralocorticoid and apparent mineralocorticoid syndromes of secondary hypertension. Adv. Chronic. Kidney Dis. 22(3), 185–195 (2015)CrossRef S. Ardhanari, R. Kannuswamy, K. Chaudhary et al. Mineralocorticoid and apparent mineralocorticoid syndromes of secondary hypertension. Adv. Chronic. Kidney Dis. 22(3), 185–195 (2015)CrossRef
32.
go back to reference H. Cui, F. Wang, L. Fan et al. Association factors of target organ damage: analysis of 17,682 elderly hypertensive patients in China. Chin Med. J. (Engl) 124(22), 3676–3681 (2011) H. Cui, F. Wang, L. Fan et al. Association factors of target organ damage: analysis of 17,682 elderly hypertensive patients in China. Chin Med. J. (Engl) 124(22), 3676–3681 (2011)
33.
go back to reference F.F. Wei, Y. Li, L. Zhang et al. Association of target organ damage with 24-hour systolic and diastolic blood pressure levels and hypertension subtypes in untreated Chinese. Hypertension 63(2), 222–228 (2014)CrossRef F.F. Wei, Y. Li, L. Zhang et al. Association of target organ damage with 24-hour systolic and diastolic blood pressure levels and hypertension subtypes in untreated Chinese. Hypertension 63(2), 222–228 (2014)CrossRef
34.
go back to reference H.E. Nelissen, M.E. Hendriks, F.W.N.M. Wit et al. Target organ damage among hypertensive adults in rural Nigeria: a cross-sectional study. J. Hypertens. 32(3), 487–494 (2014)CrossRef H.E. Nelissen, M.E. Hendriks, F.W.N.M. Wit et al. Target organ damage among hypertensive adults in rural Nigeria: a cross-sectional study. J. Hypertens. 32(3), 487–494 (2014)CrossRef
35.
go back to reference S. Reungjui, C.A. Roncal, W. Sato et al. Hypokalemic nephropathy is associated with impaired angiogenesis. J. Am. Soc. Nephrol. 19(1), 125–134 (2008)CrossRef S. Reungjui, C.A. Roncal, W. Sato et al. Hypokalemic nephropathy is associated with impaired angiogenesis. J. Am. Soc. Nephrol. 19(1), 125–134 (2008)CrossRef
36.
go back to reference A.S. Relman, W.B. Schwartz, The kidney in potassium depletion. Am. J. Med. 24(5), 764–773 (1958)CrossRef A.S. Relman, W.B. Schwartz, The kidney in potassium depletion. Am. J. Med. 24(5), 764–773 (1958)CrossRef
37.
go back to reference T. Dyckner, Relation of cardiovascular disease to potassium and magnesium deficiencies. Am. J. Cardiol. 65(23), 44k–46k (1990)CrossRef T. Dyckner, Relation of cardiovascular disease to potassium and magnesium deficiencies. Am. J. Cardiol. 65(23), 44k–46k (1990)CrossRef
38.
go back to reference B.F. Palmer, D.J. Clegg, Physiology and pathophysiology of potassium homeostasis. Adv. Physiol. Educ. 40(4), 480–490 (2016)CrossRef B.F. Palmer, D.J. Clegg, Physiology and pathophysiology of potassium homeostasis. Adv. Physiol. Educ. 40(4), 480–490 (2016)CrossRef
Metadata
Title
High incidence of hypertension-mediated organ damage in a series of Chinese patients with 17α-hydroxylase deficiency
Authors
Zhiyuan Zhao
Lin Lu
Ou Wang
Xueyan Wu
Bang Sun
Wei Zhang
Xi Wang
Jiangfeng Mao
Shi Chen
Anli Tong
Min Nie
Publication date
01-04-2022
Publisher
Springer US
Published in
Endocrine / Issue 1/2022
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-021-02966-w

Other articles of this Issue 1/2022

Endocrine 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.